Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR"mTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does Rakovina Therapeutics Inc (RKV) operate in?
Rakovina Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Rakovina Therapeutics Inc (RKV) current stock price?
As of the latest data, Rakovina Therapeutics Inc stock price is CA$0.15, with a previous close of CA$0.17. Rakovina Therapeutics Inc lost -CA$0.02 in the last trading session, representing a -11.76% loss.
What is Rakovina Therapeutics Inc (RKV) current market capitalization?
Rakovina Therapeutics Inc market cap is approximately 3.66 million.
What is Rakovina Therapeutics Inc (RKV) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.41, and the forward EPS is CA$1.70.
Does Rakovina Therapeutics Inc (RKV) pay dividends?
No. Rakovina Therapeutics Inc does not pay a dividend.
When is Rakovina Therapeutics Inc (RKV) next earnings report?
Rakovina Therapeutics Inc is expected to release its next earnings report on June 30, 2026.
What is Rakovina Therapeutics Inc (RKV) beta (volatility) score?
Rakovina Therapeutics Inc has a beta of -0.218, indicating lower volatility than the overall market.
